Level 23, 180 George Street
Salesforce Tower
Sydney, NSW 2000
Australia
61 2 9256 2505
https://www.recce.com.au
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees:
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. John K. A. Prendergast Ph.D. | Executive Chairman of the Board | 369.85k | N/A | 1954 |
Mr. James Hamilton-Bray Graham GAICD | CEO, MD & Executive Director | 774.73k | N/A | N/A |
Ms. Michele Keryn Diliza BA (Journ), BSc (Med Sci) | Chief Scientific Director & Executive Director | 539.34k | N/A | N/A |
Dr. Justin Ward | Principal Quality Chemist & Executive Director | 306.76k | N/A | N/A |
Mr. Arthur Kollaras | Principal Engineer & Head of Manufacturing | 319.12k | N/A | N/A |
Dr. Alan W. Dunton B.Sc., M.D. | Chief Medical Advisor & Independent Non Executive Director | 72.5k | N/A | 1954 |
Mr. Justin Reynolds | Chief Financial Officer | N/A | N/A | N/A |
Mr. Daniel Astudillo B.A., B.Com., M.B.A. | Head of Marketing | N/A | N/A | N/A |
Ms. Maggie Niewidok | Company Secretary | N/A | N/A | N/A |
Recce Pharmaceuticals Ltd, a biotechnology company, discovers, develops, and commercializes synthetic antiinfectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotic formulated for oral use. In addition, the company engages in R327 Intravenous which provides serious/life-threatening bacterial infections, including sepsis which is in the phase 1 trial; urinary tract infections, including urosepsis; rapid infusions sepsis in the phase 2 trial; and R327 Topical offers wound infections, including infected burns; and diabetic foot ulcer infections in Phase 2 trails. Further, the company operates various pre-clinical programs, such as Mycobacterium abscessus which is in phase 1 clinical trial; bacterial sinusitis; and additional TBA. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.
Recce Pharmaceuticals Ltd’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.